SynCon® HIV vaccines
Human immunodeficiency virus (HIV) is a retrovirus that causes acquired immunodeficiency syndrome (AIDS), a condition in humans in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive. HIV is divided into two distinct types, HIV-1 and HIV-2, which display biological and clinical distinctions. Most HIV research focuses on
There are six HIV-1 subtypes, or clades: A, B, C, D, E and AE; they tend to be geographically oriented. Inovio’s strategy is to advance HIV synthetic vaccines pertinent to distinct geographic areas through multiple collaborations to fund and conduct relevant clinical studies, as shown in the table below.
Inovio’s vaccines are unique in being able to generate both preventive and therapeutic immune responses.
|Candidate||Geographic Focus||Target Envelope Clades||Target Antigens||Collaborator|
|Clade B||Gag, pol, env||Prophylactic study: HIV Vaccine Trials
Therapeutic study: U. of Pennsylvania
|PENNVAX®-G||Developing regions of Africa and Asia||Clades A, C, D||Gag, pol||USMHRP/NIAID|
|PENNVAX®-GP||Developing regions of Africa and Asia||Clades A, C||Gag, env||NIH/NIAID|